Ozempic logos flashed courtside at professional matches this year. The WADA List Expert Advisory Group responded. On September 1, 2026, the World Anti-Doping Agency placed GLP-1 receptor agonists on its 2026 monitoring list. This does not mean athletes are banned from using these medications Pharmacy Times.
The regulatory line is sharp. GLP-1 receptor agonists are not on the WADA Prohibited List. No therapeutic use exemption is required. No athletic sanction follows a positive finding. WADA is tracking usage patterns.
The distinction matters for athletes under out-of-competition testing. A monitored substance appears on no banned list. Its presence in the monitoring program means laboratories can capture prevalence data during routine doping checks. "Semaglutide and tirzepatide were added to the monitoring program to track patterns of use in sports, in and out of competition," WADA head of media relations James Fitzgerald stated.
Semaglutide entered monitoring in 2024. Tirzepatide markers joined the 2026 program. Neither compound crossed into prohibition.
The Two-of-Three Threshold
WADA does not move a substance to prohibition without clearing a defined bar. A drug must meet at least two of three criteria: performance enhancement, health risk to the athlete, or violation of the "spirit of sport" Pharmacy Times.
GLP-1 receptor agonists touch all three. Less body mass shifts power-to-weight ratios in weight-sensitive events. Muscle loss carries documented health consequences. Off-label use among non-overweight athletes raises questions about medical necessity. WADA has made no determination that these drugs enhance performance. The monitoring program builds the evidence base that could justify a future prohibition. That process takes years.
Related enforcement actions have already tested the boundaries of peptide regulation, including when usada suspends weightlifter for peptide use, igniting 'peptide ban' debate in elite sports and when usada bans weightlifter for peptide use under strict liability rules.
The Fueling Problem
The mechanism drives the surveillance. GLP-1 receptor agonists suppress appetite and delay gastric emptying. For a patient managing metabolic disease, that is the therapeutic goal. For an athlete in a high-volume training block, it creates a fuel crisis.
Suppressed appetite reduces caloric intake. Delayed gastric emptying slows nutrient absorption. Glycogen repletion suffers. Endurance output drops. Power fades. Appetite suppression "can unintentionally drive low energy availability, which may increase the risk of injury, illness, and impaired recovery" Pharmacy Times.
That is a risk profile. The mechanism that makes these drugs effective for weight loss undermines the fueling demands of elite training. No published trials show semaglutide or tirzepatide makes competitive runners faster. WADA is funding a trial to test how semaglutide changes runners' body composition and performance.
Online communities accelerate the circulation. Fitness forums circulate off-label protocols while regulatory bodies map the terrain. Parallel enforcement actions shape the landscape, such as when the fda targets retatrutide sellers with five september warning letters to address unapproved compounds moving through digital networks. Athletes navigating strict liability frameworks must parse community signals against governing-body records.
The approved Pharmacy Times report does not document positive out-of-competition tests, biological passport anomalies, or athletic sanctions resulting from this 2026 monitoring placement. WADA added tirzepatide markers to the monitoring program in January 2026, expanding a surveillance effort on semaglutide that began in 2024.
